Native human IFN-α is a more potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-α

Journal of Interferon and Cytokine Research

Volumn 27, Issue 6, 2007, Pages 481-490

  Šantak, Goran ^a   Šantak, Maja ^b   Forčić, Dubravko ^b  

^a General County Hospital   (Croatia)

^b INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON K; ALPHA SMOOTH MUSCLE ACTIN; INTERFERON ALPHA B2; INTERLEUKIN 4; MESSENGER RNA; PROCOLLAGEN; RECOMBINANT ALPHA INTERFERON; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERFERON PRODUCTION; PRIORITY JOURNAL; SENDAI VIRUS; SKIN FIBROBLAST; STIMULUS RESPONSE; WOUND HEALING;

ACTINS; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; INTERLEUKIN-4; RNA, MESSENGER; SKIN; TRANSFORMING GROWTH FACTOR BETA;

SENDAI VIRUS;

EID: 34250886221     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0174     Document Type: Article

References (56)

1. Desmouliere A. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell. Biol. Int. 1995;19:471-476.
2. Lijnen P, Petrov V. Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find. Exp. Clin. Pharmacol. 2002;24:333-344.
3. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat. Rev. Mol. Cell. Biol. 2002;3:349-363.
4. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18:816-827.
5. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 2005;13: 7-12.
6. Faler BJ, Macsata RA, Plummer D, Mishra L, Sidawy AN. Transforming growth factor-beta and wound healing. Perspect. Vasc. Surg. Endovasc. Ther. 2006;18:55-62.
7. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell. Biol. 1993;122:103-111.
8. Gabbiani G. The biology of the myofibroblast. Kidney Int. 1992; 41:530-532.
9. Hewitson TD, Wu HL, Becker GJ. Interstitial myofibroblasts in experimental renal infection and scarring. Am. J. Nephrol. 1995; 15:411-417.
10. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab. Invest. 2003,83:1689-1707.
11. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J. Clin. Invest. 1984;74:1112-1116.
12. Ghahary A, Shen Q, Rogers JA, Wang R, Fathi-Afshar A, Scott PG, Tredget EE. Liposome-associated interferon-alpha-2b functions as an anti-fibrogenic factor for human dermal fibroblasts. J. Invest. Dermatol. 1997;109:55-60.
13. Fort J, Pilette C, Veal N, Oberti F, Gallois Y, Douay O, Cales P. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J. Hepatol. 1998;29:263-270.
14. Tredget EE, Shankowsky HA, Pannu R, Nedelec B, Iwashina T, Ghahary A, Taerum TV, Scott PG. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast. Reconstr. Surg. 1998;102:1317-1328.
15. Ghahary A, Tredget EE, Shen Q, Kilani RT, Scott PG, Takeuchi M. Liposome associated interferon-alpha-2b functions as an antifibrogenic factor in dermal wounds in the guinea pig. Mol. Cell. Biochem. 2000;208:129-137.
16. Tredget EE, Wang R, Shen Q, Scott PG, Ghahary A. Transforming growth factor-β mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-α and IFN-γ in vitro and in vivo. J. Interferon Cytokine Res. 2000;20:143-151.
17. Nedelec B, Shankowsky H, Scott PG, Ghahary A, Tredget EE. Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b. Surgery 2001;130:798-808.
18. Chang XM, Chang Y, Jia A. Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis. World J. Gastroenterol. 2005;11:2634-2636.
19. Lee JP, Jalili RB, Tredget EE, Demare JR, Ghahary A. Antifibrogenic effects of liposome-encapsulated IFN-α2b cream on skin wounds in a fibrotic rabbit ear model. J. Interferon Cytokine Res. 2005;25:627-631.
20. Thompson JA, Brady J, Kidd P, Fefer A. Recombinant alpha-2 interferon in the treatment of hairy cell leukemia. Cancer Treat. Rep. 1985;69:791-793.
21. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:105-123.
22. Chen M, Wang GJ, Diao Y, Xu RA, Xie HT, Li XY, Sun JG. Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo. World J. Gastroenterol. 2005;11:4045-4051.
23. Nagata S, Mantei N, Weissmann C. The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha. Nature 1980;287:401-408.
24. Zidovec S, Mazuran R. Immunogenic PDGF-AB dimers in crude leukocyte interferon batches. Cytokine 1998;10:70-72.
25. Zidovec S, Mazuran R. Sendai virus induces various cytokines in human peripheral blood leukocytes: different susceptibility of cytokine molecules to low pH. Cytokine 1999;11:140-143.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987;162:156-159.
27. Postlethwaite AE. Role of T cells and cytokines in effecting fibrosis. Int. Rev. Immunol. 1995;12:247-258.
28. Rennard SI. Inflammation and repair processes in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160:S12-S16.
29. Schnaper HW, Kopp JB, Poncelet AC, Hubchak SC, Stetler-Stevenson WG, Klotman PE, Kleinman HK. Increased expression of extracellular matrix proteins and decreased expression of matrix proteases after serial passage of glomerular mesangial cells. J. Cell. Sci. 1996;109:2521-2528.
30. Moreno MG, Muriel P. Remission of liver fibrosis by interferon-alpha 2b. Biochem. Pharmacol. 1995;50:515-520.
31. Dogukan A, Akpolat N, Celiker H, Ilhan N, Halil Bahcecioglu I, Gunal AI. Protective effect of interferon-alpha on carbon tetrachloride-induced nephrotoxicity. J. Nephrol. 2003;16:81-84.
32. Rubinchik E, Levi-Schaffer F. Interleukin-2 inhibits 3T3 fibroblast proliferation. Life Sci. 1996;58:1509-1517.
33. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am. J. Respir. Cell. Mol. Biol. 1999;21:658-665.
34. Hu B, Wu Z, Jin H, Hashimoto N, Liu T, Phan SH. CCAAT/enhancer-binding protein β isoforms and the regulation of α-smooth muscle actin gene expression by IL-1 beta. J. Immunol. 2004; 173:4661-4668.
35. Mauviel A, Daireaux M, Redini F, Galera P, Loyau G, Pujol JP. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett. 1988;236:47-52.
36. Harrop AR, Ghahary A, Scott PG, Forsyth N, Uji-Friedland A, Tredget EE. Regulation of collagen synthesis and mRNA expression in normal and hypertrophic scars fibroblasts in vitro by interferon-gamma. J. Surg. Res. 1995;58:471-477.
37. Kitzis V, Engrav LH, Quinn LS. Transient exposure to tumor necrosis factor-alpha inhibits collagen accumulation by cultured hypertrophic scar fibroblasts. J. Surg. Res. 1999;87:134-141.
38. Siwik DA, Chang DL-F, Colucci WS. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ. Res. 2000;86:1259-1265.
39. Sasaki M, Kashima M, Ito T, Watanabe A, Izumiyama N, Sano M, Fujiwara Y, Miura M. Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1β and TNF-α. Mediat. Inflamm. 2000;9: 155-160.
40. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM, Dooley S. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin. Gastroenterol. Hepatol. 2005;3:819-828.
41. Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 2006;3:330-338.
42. Kessler DS, Pine R, Pfeffer LM, Levy DE, Darnell JE Jr. Cells resistant to interferon are defective in activation of a promoter-binding factor. EMBO J. 1988;7:3779-3783.
43. Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R. Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res. 1992;52:1087-1090.
44. Yang C-H, Murti A, Pfeffer LM. Stat3 complements defects in an interferon-resistant cell line: evidence for an essential role for Stat3 in interferon signaling and biological activities. Proc. Natl. Acad. Sci. USA 1998;95:5568-5572.
45. Wells RG. Fibrogenesis. V. TGF-beta signaling pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 2000;279:845-850.
46. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr. Rheumatol. Rep. 2006;8:145-150.
47. Zhang H-Y, Gharaee-Kermani M, Phan SH. Regulation of lung fibroblast α-smooth muscle actin expression, contractile phenotype, and apoptosis by IL-1β. J. Immunol. 1997;158:1392-1399.
48. Shephard P, Martin G, Smola-Hess S, Brunner G, Krieg T, Smola H. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am. J. Pathol. 2004;164:2055-2066.
49. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 1992;90:1479-1485.
50. Sempowski GD, Derdak S, Phipps RP. Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J. Cell. Physiol. 1996;167:290-296.
51. Salmon-Ehr V, Serpier H, Nawrocki B, Gillery P, Clavel C, Kalis B, Birembaut P, Maquart FX. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch. Dermatol. 1996;132:802-806.
52. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum. 1992;35:67-72.
53. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch. Dermatol. Res. 1995; 287:193-197.
54. Fertin C, Nicolas JF, Gillery P, Kalis B, Banchereau J, Maquart FX. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell. Mol. Biol. 1991; 37:823-829.
55. Gillery P, Fertin C, Nicolas JF, Chastang F, Kalis B, Banchereau J, Maquart FX. Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett. 1992;302:231-234.
56. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur. J. Immunol. 1998;28:2619-2629.